| N-substituted heterocycles for the treatment of hypercholesteremia, dyslipidemia and other metabolic disorders; cancer, and other diseases -> Monitor Keywords |
|
|
 
N-substituted heterocycles for the treatment of hypercholesteremia, dyslipidemia and other metabolic disorders; cancer, and other diseasesRelated Patent Categories: Drug, Bio-affecting And Body Treating Compositions, Designated Organic Active Ingredient Containing (doai), Heterocyclic Carbon Compounds Containing A Hetero Ring Having Chalcogen (i.e., O,s,se Or Te) Or Nitrogen As The Only Ring Hetero Atoms Doai, Hetero Ring Is Six-membered And Includes At Least Nitrogen And Oxygen As Ring Hetero Atoms (e.g., Monocyclic 1,2- And 1,3-oxazines, Etc.), Polycyclo Ring System Having The Six-membered Hetero Ring As One Of The Cyclos (e.g., Maytansinoids, Etc.), Bicyclo Ring System Having The Six-membered Hetero Ring As One Of The Cyclos (e.g., 1,4-benzoxazines, Etc.)N-substituted heterocycles for the treatment of hypercholesteremia, dyslipidemia and other metabolic disorders; cancer, and other diseases description/claimsThe Patent Description & Claims data below is from USPTO Patent Application 20060160796, N-substituted heterocycles for the treatment of hypercholesteremia, dyslipidemia and other metabolic disorders; cancer, and other diseases. Brief Patent Description - Full Patent Description - Patent Application Claims
RELATED APPLICATIONS [0001] This application is a divisional of and claims priority to U.S. Nonprovisional application Ser. No. 10/298,024, filed Nov. 11, 2002, the disclosure of which application is hereby incorporated in its entirety by this reference, which claims priority to U.S. Provisional Application Ser. No. 60/334,794, filed Nov. 15, 2001; to U.S. Provisional Application 60/362,702, filed Mar. 8, 2002; and to U.S. Provisional Application 60/362,732, filed Mar. 8, 2002, which are all hereby incorporated herein by reference in their entireties. BACKGROUND OF THE INVENTION [0002] Metabolic disorders such as obesity, Type 2 diabetes, dyslipidemia and hyper-cholesteremia have dramatically increased in the United States, other developed countries and even in some developing countries due to a combination of high calorie, high lipid content diets and sedentary life styles. Among other things, patients suffering from the above disorders or diseases are at risk for the development of artherosclerosis and heart disease, which are the second most frequent cause of death in the U.S. Dietary restrictions combined with exercise are known to be useful for the prevention, and in some cases, reversal of the above metabolic disorders, but have turned out to be rather ineffective when looking at populations in general. Drug treatment, therefore, appears presently to be necessary to prevent and treat metabolic disorders such as obesity, Type 2 diabetes, dyslipidemia and hypercholesteremia, and thereby prevent the development of serious side effects in particular cardiovascular disease. While a number of drugs have been developed over the years to treat the various metabolic disorders, these drugs can often have side effects or are effective only for a limited time period or function only in combination with dietary restrictions. [0003] Compounds having activity for treating diabetes and related metabolic disorders were disclosed in PCT publications WO 01/16122 and WO 01/16123, both published Mar. 8, 2001. The disclosures of both WO 01/16122 and WO 01/16123 are hereby ncorporated in their entirities by this reference, for all purposes, and particularly for heir disclosures of the structures of their compounds and their biological activities and tilities. [0004] Additionally, solid tumors are the leading cause of death attributable to cancers worldwide. Conventional methods of treating cancer include surgical treatments, the administration of chemotherapeutic agents, and recently immune based treatments, which typically involve the administration of an antibody or antibody fragment. Although some encouraging results are being reported with the latter, an effective, life-prolonging treatment or a cure is not yet available for most cancers. SUMMARY OF THE INVENTION [0005] In accordance with the purposes of this invention, as embodied and broadly described herein, this invention, in one aspect, relates to certain novel compounds, compositions comprising the compounds, and methods related to the regulation of metabolism and the treatment of cancer by administering the compounds and/or compositions of the invention to animals and/or humans. [0006] Described herein are novel substituted heterocyclic compounds that are useful for the treatment of certain metabolic disorders including Type 2 diabetes, dyslipidemia and hypercholesteremia. The compounds of the invention are believed to be ligands for the nuclear receptors RXR, PPAR.alpha., PPAR.gamma., PPAR.delta., LXR and/or FXR or other targets wich could be important proteins such as kinases and/or phosphatases that are involved in metabolic disorders. The compounds of the invention can also have anticancer activities in view of their abilitity to inhibit AKT Kinase. AKT, also called PKB, is the cellular homologue of the transforming viral oncogene v-AKT. Deregulation of AKT activity can be associated with oncogenic activity, and AKT is overexpressed in certain cancers and/or diseases of uncontrolled cellular proliferation, including pancreatic and ovarian carcinomas. Therefore, the compounds of the invention that inhibit AKT can have anticancer activity. In summary, the compounds and/or compositions described herein are useful for the treatment of metabolic disorders and/or cancer. [0007] Additional advantages of the invention will be set forth in part in the description which follows, and in part will be obvious from the description, or may be learned by practice of the invention. The advantages of the invention will be realized and attained by means of the elements and combinations particularly pointed out in the appended claims. It is to be understood that both the foregoing general description and the following detailed description are exemplary and explanatory only and are not restrictive of the invention, as claimed. BRIEF DESCRIPTION OF THE DRAWINGS [0008] FIG. 1 shows the total cholesterol levels in HSD Rats maintained on an atherogenic diet after treatment with Compound 7. [0009] FIG. 2 shows the HDL cholesterol levels in HSD Rats maintained on an atherogenic diet after treatment with Compound 7. [0010] FIG. 3 shows the LDL cholesterol levels in HSD Rats maintained on an atherogenic diet after treatment with Compound 7. [0011] FIG. 4 shows representative examples of methods for the synthesis of compounds disclosed herein. [0012] FIG. 5 shows the inhibition of AKT/PKB Kinase activity after treatment with Compounds of the invention. [0013] FIG. 6 shows methods for synthesizing synthetic precursors of certain amide compounds disclosed herein. [0014] FIG. 7 shows methods for synthesizing synthetic precursors of certain ether compounds disclosed herein. [0015] FIG. 8 shows methods for synthesizing synthetic precursors of certain thioether compounds disclosed herein. [0016] FIG. 9 shows methods for synthesizing synthetic precursors of certain amine compounds disclosed herein. [0017] FIG. 10 shows methods for synthesizing synthetic precursors of certain substituted aromatic compounds disclosed herein. [0018] FIG. 11 shows the profile of adipocyte differentiation displayed when 3T3-L1 cells were treated with the compounds of the invention by themselves or in the presence of rosiglitazone (BRL49653). [0019] FIG. 12 shows antagonism of T0901317-dependent activation of LXR and BRL49653-dependent activation of PPAR.gamma. by the compounds of the invention. [0020] FIG. 13 shows results of tests for the activity of the compounds of the invention with respect to human cell cultures for breast cancer (MDA-MB-468), prostate cancer (PC-3), pancreatic cancer (Bx-PC3), and non-small cell lung cancer (A549) cells. Continue reading about N-substituted heterocycles for the treatment of hypercholesteremia, dyslipidemia and other metabolic disorders; cancer, and other diseases... Full patent description for N-substituted heterocycles for the treatment of hypercholesteremia, dyslipidemia and other metabolic disorders; cancer, and other diseases Brief Patent Description - Full Patent Description - Patent Application Claims Click on the above for other options relating to this N-substituted heterocycles for the treatment of hypercholesteremia, dyslipidemia and other metabolic disorders; cancer, and other diseases patent application. ###  How KEYWORD MONITOR works... a FREE service from FreshPatents1. Sign up (takes 30 seconds). 2. Fill in the keywords to be monitored. 3. Each week you receive an email with patent applications related to your keywords. Start now! - Receive info on patent apps like N-substituted heterocycles for the treatment of hypercholesteremia, dyslipidemia and other metabolic disorders; cancer, and other diseases or other areas of interest. ### Previous Patent Application: Tachykinin receptor antagonists Next Patent Application: Novel compounds for use in weight loss and appetite suppression in humans Industry Class: Drug, bio-affecting and body treating compositions ### FreshPatents.com Support Thank you for viewing the N-substituted heterocycles for the treatment of hypercholesteremia, dyslipidemia and other metabolic disorders; cancer, and other diseases patent info. IP-related news and info Results in 0.33215 seconds Other interesting Feshpatents.com categories: Accenture , Agouron Pharmaceuticals , Amgen , AT&T , Bausch & Lomb , Callaway Golf 174 |
 * Protect your Inventions * US Patent Office filing 
PATENT INFO |
|
